We have previously shown both humoral and CTL responses to anaplastic lymphoma kinase (ALK) in patients with ALKpositive anaplastic large-cell lymphoma (ALCL). However, because CD4 + T-helper (Th) cells also play a vital role in developing and maintaining tumor immunity, we investigated the presence of a CD4 + Th response in ALK-positive ALCL. Using an IFN-; ELISPOT assay, we identified two ALK-derived DRB1-restricted 24-mer promiscuous peptides, ALK1 278-301 and ALK2 , as being immunogenic in six ALK-positive ALCL patients but not in two ALK-negative ALCL patients or five normal subjects. A significant interleukin-4 response to the ALK peptides was detected in only one ALK-positive patient. 
Introduction
Anaplastic large-cell lymphoma (ALCL) comprises 30% to 40% of pediatric large-cell lymphomas. The majority of ALCL are associated with the aberrant expression of anaplastic lymphoma kinase (ALK) fusion proteins and constitute the tumor entity ALKpositive ALCL (1) . ALK expression is considered to be a primary oncogenic event in ALCL, playing a pivotal role in the survival of the tumor cells (2) . This factor, combined with a lack of peripheral tolerance (due to the restricted normal distribution of ALK), identifies ALK as an ideal immunotherapeutic target (3) .
Evidence confirming ALK as a tumor-associated antigen has been obtained from studies reporting the presence and persistence not only of an antibody response to ALK (4-6) but also of ALKspecific CTLs in patients with ALK-positive ALCL (6, 7) . However, increasing evidence that CD4 + T-helper (Th) cells play a significant role in the regulation and maintenance of the CTL response to tumors (8) (9) (10) means it is important to identify CD4 + Th cell peptide-binding epitope(s) within the ALK protein to maximize the efficacy of future ALK-based immunotherapeutic strategies. We provide here the first description of a CD4 + Th response to ALK in ALK-positive ALCL patients.
Materials and Methods
Subjects. Six ALK-positive ALCL (patients 1-6) and two ALK-negative ALCL (patients 7 and 8), diagnosed according to the WHO classification (2), and five normal control subjects (normals 1-5) were studied. Following informed consent, blood was obtained from patients who were attending the Hematology Department, John Radcliffe Hospital, Oxford (patients 1, 2, 3, 7, and 8); Manchester General Hospital, Manchester (patient 4); Royal Marsden Hospital, London (patient 5); and Liverpool General Hospital, Liverpool (patient 6). Patients 4 and 5 were included in the Biological Studies project BS001 run by the United Kingdom Children's Cancer Study Group. Details of patients and samples are shown in Table 1 .
HLA typing. HLA typing was done by PCR with sequence-specific primers using a modification of the phototyping method. PCR conditions were as previously described (12) .
Peptides. The TEPITOPE prediction algorithm 3 was used to select ALK peptides predicted to bind with high affinity to DRB1 *0101, *0301, *0401, *0701, *1101, and *1501 (the most prevalent alleles among the Caucasian population; ref. 13). Three highly promiscuous peptides, ALK1 278-301 (PSSLAMLDLLHVARDIACGCQYLE), ALK2 233-256 (KFNHQN-IVRCIGVSLQSLPRFILL), and ALK3 411-434 (PKNCPGPVYRIMTQCWQHQ-PEDRP), were identified lying within the kinase domain. ALK1 278-301 encompasses the highly immunogenic ALK 280-289 CTL epitope (6, 14) . An irrelevant control peptide was HIV 121-140 (DESFRKYTAFTIPSMNNETP).
Cell lines. The t(2;5)-positive ALCL-derived cell lines SUDHL-1 (DRB1_0403) and KARPAS-299 (DRB1_0101) and the t(2;5)-negative ALCL cell line FEPD (DRB1_0301) were obtained and cultured as previously described (15) .
Preparation of peripheral blood mononuclear cells. Peripheral blood mononuclear cells (PBMCs) in RPMI 1640 containing 10% FCS (RPMI 1640/FCS) were prepared as previously described (6) . PBMCs (2 Â 10 5 ) in 200 AL were added to each well of a 96-well flat-bottomed plate and incubated for 10 days with 10 Amol/L of ALK1 278-301 , ALK2 233-256 , ALK3 411-434 , or the irrelevant HIV 121-140 peptide, or with 10 Ag/mL of phytohemagglutinin (PHA; Sigma-Aldrich Co. Ltd., Dorset, United Kingdom). Recombinant interleukin-2 (IL-2; 20 IU/mL; Roche Diagnostics, Indianapolis, IN) and recombinant human IL-7 (25 ng/mL; R&D Systems, Minneapolis, MN) were added on days 2, 5, and 7.
ELISPOT assay. After 10 days of culture, cells were incubated for 18 h in complete RPMI 1640/FCS at 37jC in 5% CO 2 with ALK1 278-301 , ALK2 233-256 , ALK3 411-434 , HIV 121-140 , or PHA, or medium only. Peptides were used at 10 Amol/L and all cultures were carried out in triplicate. IFN-g/IL-4 release ELISPOT assays were done (6) according to the manufacturer's instructions (Mabtech, Stockholm, Sweden). Spots were counted using an automated ELISPOT reader (Autoimmun-Diagnostika, Strassberg, Germany). The SD was calculated using standard techniques and Student's t test was used for statistical analysis.
CD4-enriched PBMC population. PBMCs cultured at a density of 2 Â 10 6 /mL were stimulated with 10 Amol/L of ALK1 RPMI 1640/FCS containing 50 IU/mL recombinant IL-2 was added to each culture well; every 3 days thereafter, half of the medium was removed and replaced with fresh medium. In some experiments, a CD4 + T-cell purification step was done (Dynabeads, Dynal, Oslo, Norway) following the manufacturer's instructions before the cells were used in an overnight ELISPOT assay for IFN-g release. In other experiments, the HLA-DRspecific WR18 antibody (Abcam, Cambridge, United Kingdom) was added at 2 Ag/mL to the CD4 + Th cell population for 1 h before assay.
51
Cr cytolytic assay. SUDHL-1, KARPAS-299, and FEPD cells were radiolabeled with 100 ACi 51 Cr. The target cells were then incubated for 18 h with the ALK peptide-stimulated lines and cytolysis was analyzed as previously described (6) .
Detection of the antibody response to ALK. Cytocentrifuge preparations of COS cells, which had been transiently transfected with cDNA encoding for ALK, NPM-ALK, or vector only, were prepared and stained using patient's plasma in an indirect immunoperoxidase technique as previously described (4).
Results and Discussion
A significant IFN-g response to the ALK1 278-301 and ALK2 peptides was detected in all six ALK-positive ALCL patients (P < 0.05). Peptide ALK3 411-434 was weakly immunogenic to PBMCs from patient 4 only ( Table 2 ). All six patients exhibited an antibody response to ALK ( Table 2 ). The absence of an IFN-g response in patients with ALK-negative ALCL and normal controls shows the specificity of the anti-ALK responses observed here. The ability of peptides to stimulate an IFN-g response from patients displaying different HLA-DRB1 alleles possibly reflects the potential promiscuity of these peptides enabling them to recognize and interact with various HLA-DRB1 alleles (13) .
The detection of a significant IL-4 response in patient 2 only (Table 2) suggests the presence of an IFN-g-driven Th1 type response to the ALK peptides. This is of interest because the majority of the ALK-positive patients studied are currently in remission. Previous reports have described that melanoma patients who remained disease-free exhibited highly polarized Th1 immune responses (16) . In contrast, progressive disease was skewed towards Th2 or Th1/Th2 responses in a murine leukemia/ lymphoma model (17) .
Increased IFN-g responses to ALK peptides ALK1 278-301 (>80%) and ALK2 233-256 (>100%) were detected following repeated peptide stimulation of PBMCs (Fig. 1A) . Depletion of the CD4 + cell population or the addition of anti-HLA-DR abrogated the IFN-g response to both peptides (Fig. 1B) , supporting the CD4 + -mediated and DRB1-restricted nature of this response.
The presence of a significant IFN-g response in patient 2 at time of diagnosis and after 1 year in remission ( Fig. 1C ; P < 0.05) suggests the presence of a pool of memory CD4 + Th cell subsets. Such cells could play an important role not only in protective tumor immunity (18) but also in the maintenance of the CD8 + memory CTLs previously reported in ALK-positive ALCL (6, 7) .
CD4
+ Th cell lines specific for ALK1 278-301 and ALK2 233-256 raised from patient 2 PBMCs lysed ALK-positive SUDHL-1 and KARPAS-299 cells ( Fig. 1D ; P < 0.001) despite the fact that the ALK-positive cell lines express different HLA-DRB1 alleles. A possible explanation is the high degree of homology between the DRB1_0403 and DRB1_0101 molecules. 4 No significant lysis was detected of the ALK-negative FEPD cell line. Thus, the CD4 + Th cells were capable of recognizing endogenous ALK peptides on the ALK-positive tumor cells.
Studies have shown the potential of using epitopes predicted to bind to both MHC Class I and Class II to obtain more effective immune responses (19, 20) . The ALK1 278-301 peptide encompassing a CTL epitope previously shown to be immunogenic in ALKpositive patients (7) could, therefore, represent an attractive peptide for inclusion in a vaccine formulation.
We show, for the first time, ALK peptides capable of eliciting strong CD4 + Th responses in patients with ALK-positive ALCL. These peptides constitute potential vaccine candidates for ALKpositive patients who respond poorly to conventional treatment. Cr release cytolytic assays. A to C, PBMCs were maintained in culture and stimulated with ALK1 278-301 and ALK2 233-256 peptides for 10 d. CD4
+ Th cell lines were raised after 6 wk of repeated stimulation with ALK peptides. A, the CD4 + Th-enriched cells showed a significantly increased IFN-g response to both ALK peptides when compared with PBMC cultures (P < 0.05). In contrast, no significant response to the control HIV peptide or medium only was observed. B, CD4 + cells were prepared using a magnetic purification step. After overnight incubation with the ALK1 278-301 and ALK2 233-256 peptides in an ELISPOT assay, the CD4 + cells released IFN-g in response to both ALK peptides. No significant response was detected to the irrelevant control peptide. The use of a CD4 + depletion step or the addition of anti-HLA-DR antibody abrogated the IFN-g response to the ALK peptides. C, monitoring the CD4 + Th responses of this patient at time of diagnosis and during remission shows that responses to both peptides remained significantly high even after 1 y (P < 0.05). D to F, the cytolytic activity of CD4 + Th cell lines raised from patient 2 against ALK1 278-301 and ALK2 233-256 peptides was tested in an 18-h Cr release assay on the ALK-positive SUDHL-1 (DRB1_0403) and KARPAS-299 (DRB1_0101) and the ALK-negative FEPD (DRB1_0301) ALCL-derived cell lines. Significant lysis, even at an effector/target ratio of 3:1, was observed in cultures containing the ALK-positive SUDHL-1 (D ) or KARPAS-299 (E) cells. This was in contrast to the lack of lysis observed of the ALK-negative FEPD cell line (F ). No significant lysis was observed with CD4 + Th cells raised against the irrelevant peptide (HIV 121-140 ). The results are the mean +/À SD and were from triplicate cultures.
